gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

Artikel

Artikel empfehlen

An open prospective pilot study for the use of Rapamycin after high-risk keratoplasty

Meeting Abstract

Suche in Medline nach

  • corresponding author F. Birnbaum - Eye-Hospital, Albert-Ludwigs University, Freiburg
  • T. Reinhard - Eye-Hospital, Albert-Ludwigs University, Freiburg
  • J. Sokolowska - Eye-Hospital, Heinrich-Heine University, Düsseldorf
  • K. Mayer - Eye-Hospital, Heinrich-Heine University, Düsseldorf
  • A. Reis - Eye-Hospital, Heinrich-Heine University, Düsseldorf
  • M. Oellerich - Center of Internal Medicine, Department of Clinical Chemistry, Georg-August University, Göttingen
  • R. Sundmacher - Eye-Hospital, Heinrich-Heine University, Düsseldorf

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogP 037

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dog2004/04dog528.shtml

Veröffentlicht: 22. September 2004

© 2004 Birnbaum et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.

Gliederung

Text

Objective

Until now cyclosporine A (CSA) and mycophenolate-mofetil (MMF) are the only available systemic immunosuppressants for patients undergoing high-risk keratoplasty. Rapamycin has shown its immunosuppressive potential in the rat keratoplasty model. After kidney transplantation Rapamycin is part of several immunosuppressive protocols. Aim of this study was to prove the efficacy and safety of Rapamycin after penetrating high-risk keratoplasty.

Methods

Ten patients undergoing high-risk keratoplasty were included in this study. Postoperative medication was Fluocortolon 1 mg/kg/d (tapered off within 3 weeks) and Prednisolonacetate eye-drops 5x/d (tapered off within 5 months). Rapamycin was administered orally once daily (blood-trough-level 4-10 ng/ml) for 6 months. Thereafter, it was tapered off within 2 weeks.

Results

Mean follow-up is 378 days. Until now two immune reactions occurred, both of them after cessation of immunosuppression. 8 patients had partly reversible side-effects as hypercholesteremia, furunculosis, exanthem, diarrhea, epistaxis, anemia or elevation of LDH. One patient was excluded from the study due to a pneumonia after pulmonary embolism.

Conclusions

Rapamycin seems to have a similar efficacy as CSA and MMF in preventing immune reactions after high-risk keratoplasty. A broad spectrum of side-effects, however, was observed.